Machine Learning Research Engineer, Isomorphic Labs

Salary not provided
Tensorflow
CUDA
PyTorch
Junior, Mid and Senior level
London

More information about location

3 days a week in office

Isomorphic Labs

AI-driven drug discovery and development

Be an early applicant

Isomorphic Labs

AI-driven drug discovery and development

201-500 employees

Artificial IntelligenceBiologyMachine LearningScienceBiotechnology

Be an early applicant

Salary not provided
Tensorflow
CUDA
PyTorch
Junior, Mid and Senior level
London

More information about location

3 days a week in office

201-500 employees

Artificial IntelligenceBiologyMachine LearningScienceBiotechnology

Company mission

To use AI and machine learning methods to accelerate and improve the drug discovery process.

Company mission

To use AI and machine learning methods to accelerate and improve the drug discovery process.

Top investors

30% female employees

Our take

The discovery of new drugs is essential for medical innovations, but the process is lengthy, high-risk, and expensive. This is due to manual research and analysis processes that are prone to human error and time-consuming workflows, raising the question as to whether AI could reduce these pitfalls.

Rather than bolting machine learning onto the existing drug discovery process, Isomorphic Labs is reimagining everything from first principles with an AI-first approach, leveraging machine learning to build predictive and generative models of biological phenomena to understand how novel drugs could perform. And the company differentiates itself from other AI-driven drug discovery startups by being a direct subsidiary of Alphabet, with access to resources, computing power, and partnerships with teams within DeepMind.

Now, the company is gearing up for its biggest leap yet - testing its AI-designed medicines on real people. After years of development, big-name partnerships, and a $600M funding round, Isomorphic says human clinical trials are finally within reach. In its London offices, scientists and AI are already teaming up to design potential treatments for diseases like cancer. The next step is putting those drugs to the test.

Kirsty headshot

Kirsty

Company Specialist at Welcome to the Jungle

Company values

  • Thoughtful: Thoughtful at Iso is about curiosity, creativity and care. It is about good people doing good, rigorous and future-making science every single day
  • Brave: Brave at Iso is about fearlessness, but it’s also about initiative and integrity. The scale of the challenge demands nothing less
  • Determined: Determined at Iso is the way we pursue our goal. It’s a confidence in our hypothesis, as well as the urgency and agility needed to deliver on it. Because disease won’t wait, so neither should we
  • Together: Together at Iso is about connection, collaboration across fields and catalytic relationships. It’s knowing that transformation is a group project, and remembering that what we’re doing will have a real impact on real people everywhere

Funding (1 round)

Mar 2025

$600m

LATE VC

Total funding: $600m

This company has top investors

Leadership

Demis Hassabis

(Co-Founer & CEO)

Co-founded Google DeepMind in 2010 and has served as the CEo ever since.

Isomorphic Labs 1Isomorphic Labs 2Isomorphic Labs 3Isomorphic Labs 4Isomorphic Labs 5